 All subjects will be kept under medical observation during the study with a daily unstructured interview and any additional investigation if needed, and any relevant change in clinical status, including any treatment-emergent adverse event, will be recorded in the CRF. During the 67-day observation period, subjects may undergo any clinical and laboratory investigations eg., hematology and blood chemistry tests, neuroimaging tests, EEGs as clinically indicated for their condition. 